Multiple Roles of BRIT1/MCPH1 in DNA Damage Response, DNA Repair, and Cancer Suppression by Lin, Shiaw-Yih et al.
Yonsei Med J   http://www.eymj.org    Volume 51   Number 3   May 2010 295
The replication of mammalian cells is a high-fidelity process that assures an
accurate passage of genomic information to the daughter cells. However, their
genome is constantly challenged by endogenous metabolic byproducts and
environmental factors that lead to the improper presence of single-strand DNA
breaks (SSBs) and/or double-strand DNA breaks (DSBs). 
Among all the types of damage, DSBs pose the greatest challenge to cells, and
are dangerous and potentially lethal lesions.
1 The DNA-damaging agents such as
ionizing radiation, reactive oxygen species can cause DSBs in the cells.
2 A DNA
replication fork that encounters DNA single-strand breaks or other types of lesions
will also produce DSBs. They can also occur at the ends of chromosomes due to a
defective metabolism of telomeres.
3,4 In addition, DNA DSBs can form in a pro-
grammed manner during development.
5,6 Those breaks are generated to initiate
recombination between homologous chromosomes during meiosis and occur as
intermediates during developmentally regulated rearrangements, such as V(D)J
recombination and immunoglobulin class-switch recombination. For a cell, to
preserve genome integrity, DSBs need to be repaired promptly, and the repair can
be fulfilled through two independent but not mutually exclusive mechanisms
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Mammalian cells are frequently at risk of DNA damage from both endogenous and exogenous sources. Accordingly,
cells have evolved the DNA damage response (DDR) pathways to monitor and assure the integrity of their genome. In
cells, the intact and effective DDR is essential for the maintenance of genomic stability and it acts as a critical barrier to
suppress the development of cancer in humans. Two central kinases for the DDR pathway are ATM and ATR, which
can phosphorylate and activate many downstream proteins for cell cycle arrest, DNA repair, or apoptosis if the damages
are irreparable. In the last several years, we and others have made significant progress to this field by identifying BRIT1
(also known as MCPH1) as a novel key regulator in the DDR pathway. BRIT1 protein contains 3 breast cancer carboxyl
terminal (BRCT) domains which are conserved in BRCA1, MDC1, 53BP1, and other important molecules involved in
DNA damage signaling, DNA repair, and tumor suppression. Our in vitro studies revealed BRIT1 to be a chromatin-
binding protein required for recruitment of many important DDR proteins (ATM, MDC1, NBS1, RAD51, BRCA2) to
the DNA damage sites. We recently also generated the BRIT1 knockout mice and demonstrated its essential roles in
homologous recombination DNA repair and in maintaining genomic stability in vivo. In humans, BRIT1 is located on
chromosome 8p23.1, where loss of hetero-zigosity is very common in many types of cancer. In this review, we will
summarize the novel roles of BRIT1 in DDR, describe the relationship of BRIT1 deficiency with cancer development,
and also discuss the use of synthetic lethality approach to target cancers with HR defects due to BRIT1 deficiency.
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THE KEY PATHWAYS FOR DNA DAMAGE RESPONSEinitiated by DDR: error prone non-homologous end join-
ing (NHEJ) or relatively error-free homologous recombi-
nation (HR).
1 
In the host, DNA damage response (DDR) pathways are
activated to respond to DNA breaks to maintain genomic
integrity. The DNA damage response involves the sensing
of DNA damage followed by transduction of the damage
signal to a network of cellular pathways including cell
cycle checkpoints, DNA repair, and the apoptotic pathway.
In general, the DDR network consists of two major parallel
pathways that respond to SSB or DSB.
7-10 In this network,
two phosphatidylinositol-3-related kinases, ataxia telangi-
ectasia mutated (ATM) and ATM-Rad3-related (ATR),
which are located at the top of the signal cascades, phos-
phorylate and activate a variety of molecules to execute the
DNA damage responses.
7-10 ATM is activated primarily by
double-strand breaks induced by ionizing irradiation and
acts during all phases of the cell cycle, whereas the ATR
pathway responds to agents interfering with functions of
DNA replication forks, such as ultraviolet light and hydro-
xyurea.
7,11 ATM can also activate many of the downstream
targets of the ATR pathway, indicating that the two major
pathways of the DDR are interlaced in a cell.
ATM and ATR are proximal kinases that act as the core
sensors and are central to the entire DDR. These two kina-
ses, by collaborating with other sensor molecules, function
to detect various forms of damaged DNA and trigger DNA
damage response cascades. For example, the complex of
MRE11-Rad50-NBS1 (MRN) is a major sensor of broken
DNA that recruits ATM to the break sites.
12-14 Several other
proteins such as 53BP1
15,16 and MDC1
17,18 also participate
in this process to locate ATM or facilitate activation of
ATM at the lesion sites of the DNA. ATM and ATR acti-
vation lead to cell cycle arrest or checkpoint via phospho-
rylation of ChK1 and ChK2.
10 For instance, ChK1 is pho-
sphorylated by ATM/ATR at Ser345 and Ser317 in res-
ponse to various types of DNA damages which can be
induced by ionizing radiation, ultraviolet, hydoxyurea, and
topoisomerase inhibitors,
19-24 ChK1, in turn, phosphorylates
the phosphatase CDC25A,
22,25 which facilitate the degra-
dation of CDC25A.
26 As a result, CDC25A can no longer
dephosphorylate and activate CDK2 and CDK1, causing
cells arrested in late G1, S, and G2 phases.
26,27 In parallel,
ChK2 is a key kinase downstream of ATM, which is pri-
marily involved in the DDR-induced apoptosis.
10
The effectors of the DDR include proteins that partici-
pate in DNA repair, transcription regulation, replication,
cell-cycle control, and apoptosis, such as CDC25, p53, and
various DNA repair proteins such as BRCA1, BRCA2,
and RAD51.
8,28 Most of these effectors are downstream
molecules of either ATM/ATR and/or ChK1/ChK2. The
ATM signaling pathway can activate and recruit BRCA1/2
proteins to the DNA damage sites. BRCA1/2 induced
double-stranded repair of breaks using HR through interac-
tion with RAD51, which is an important HR DNA repair
enzyme.
29 p53 is another protein playing a  pivotal role in
the execution of the DDR.
30 p53 can be phosphorylated and
stabilized by ATM/ATR and by another PIKK family
member, DNA-PK. p53 can also be phosphorylated by
ChK2, which itself functions as a substrate of ATM in
response to DNA damage.
9,31 The phosporylation of p53 by
these DDR kinases lead to reduced binding of p53 to
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Fig. 1. The role of BRIT1 in DNA damage response. BRIT1 functions as a key DDR protein at multiple levels. Besides of its function in checkpoint
and recruitment of many DDR proteins such as ATM, NBS1 and ATR to the damage sites, BRIT1 can modify the chromosome structure via
interaction with SWI/SNF or Condensin II. It is also directly involved in DNA repair via interaction with RAD51/BRCA2.Roles of BRIT1 in DNA Damage Response and Tumor Suppression
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MDM2, which in turn allows the replacement of ubiquitin
moieties by acetylation, resulting in p53 stabilization and
full activation.
32 Upon activation, depending on the severity
of the stress signals, the pattern of post-transcriptional modi-
fications and the cellular context, p53 acting as a potent
transcriptional activator and/or repressor can induce cell
cycle arrest and/or apoptosis,
30,33-36 and remarkably p53 has
also been shown to directly localize to sites of DNA damage
and promote proper repair.
37
Recently, BRIT1/MCPH1 has been identified as a novel
key DDR protein via the regulation of ATM/ATR path-
ways, modification of the chromosome structure, and
direct involvement in DNA repair (Fig. 1). In this review,
we will summarize the novel roles of BRIT1 in DDR, des-
cribe the relationship of BRIT1 deficiency with cancer
development, and also discuss the use of novel synthetic
lethality approach to target cancers with HR defects due to
BRIT1 deficiency.
Introduction of BRIT1
BRIT1 is a gene initially identified by a functional genomic
screen as a novel repressor of hTERT.
38 The amino acid se-
quence of BRIT1 was later matched to a putative disease
gene called microcephalin (MCPH1). Mutations of this
gene are found in a human genetic disease, primary mic-
rocephaly, which is characterized by a brain size one third
of normal.
39
BRIT1 is ubiquitously expressed in humans with higher
levels observed in the brain, testes, pancreas, and liver. Hu-
man BRIT1 protein contains 835 amino acids with about
110 kDa of the molecular weight. According to MotifScan
prediction, BRIT1 has three breast cancer carboxyl
terminal (BRCT) domains, one nuclear localization signal
motif, and a large central IMPDH domain. The BRCT
domains of BRIT1, one in N-terminus (N-BRCT), the
other two tandemly arranged in C-terminus (C-BRCTs)
specifically bind to the phosphorylated proteins commonly
involved in DNA damage response pathways. BRCT
domains are conserved in BRCA1, MDC1, NBS1, and
other important molecules involved in DNA damage
signaling, DNA repair, and tumor suppression.
40
The N-BRCT is required for centrosomal localization in
irradiated cells, and also essential to rescue the premature
chromosome condensation in BRIT1-deficient cells.
41,42 In
addition, N-BRCT is required for BRIT1’s binding to
SWI/SNF, a complex for regulation of chromosome rela-
xation.
43 The C-BRCTs direct self-oligomerization of
BRIT1, and are necessary for ionizing radiation-induced
foci formation.
41,44 The C-BRCT is also required for inter-
action and recruitment of BRCA2/RAD51 to the damage
sites for execution of HR DNA repair function.
45,46 The
function of IMPDH domain predicted by MotifScan is not
clear. However, the region (residues 376-485) in the central
IMPDH domain (or middle domain), binding with Con-
dension II, participates in homologous recombination.
42
Role of BRIT1 in cell cycle control
BRIT1 has been demonstrated to regulate the expression
of BRCA1 and Chk1, and it is required for the activation
of the intra-S and G2/M cell cycle checkpoint after cellular
exposure to ionizing radiation. In the absence of BRIT1,
BRCA1 and ChK1 expressions are significantly reduced
and NBS1 fails to be phosphorylated, leading to a loss of
intra-S and G2/M checkpoint control.
47,48 Cells derived from
a microcephaly patient (BRIT1 defective) maintain a persi-
stent level of cdc25A and a reduced level of Cdk1-clyclin
B complex, both of which attributes to the entry of mitosis.
Besides expression control of ChK1 and BRCA1, BRIT1
prevents premature entry into mitosis in an ATR-depen-
dent and ATR-independent manner.
49
BRIT1 function in DNA damage signaling as an early 
DDR mediator
BRIT1 can modulate activities of two distinct DNA
damage repair networks, the ATM pathway and the ATR
pathway. Upon exposure to DNA damaging reagents,
BRIT1 co-localizes with numerous proteins associated
with these two signaling pathways including γ-H2AX,
MDC1, 53BP1, NBS1, p-ATM, ATR, p-RAD17, and p-
RPA34.
50 In the absence of BRIT1, all of these proteins,
with the exception of γ-H2AX, fail to localize to sites of
DNA damage. The depletion of BRIT1 inhibits the recruit-
ment of phosphorylated ATM to double-stranded DNA
break ends, and subsequently impairs the phosphorylation
and recruitment of multiple down-stream members of the
ATM pathway to the DNA damage sites including MDC1,
53BP1, and NBS1. BRIT1 deficiency also abolishes the
UV-induced phosphorylation of RPA34 and reduces the
levels of phosphorylated RAD17, indicating the roles of
BRIT1 in the ATR pathway.
50 All of these studies suggest
that BRIT1 functions as a proximal factor in DDR pathway.
Using chicken cells as a study system, chicken BRIT1
can form irradiation-induced foci in ATM- and BRCA1-
deficient cells, but not in H2AX-deficient cells.
41 In addi-
tion, a study using the mouse embryonic cells (MEFs) with
MDC1 or H2AX deficiency shows that BRIT1 foci forma-
tion can occur independently of MDC1 after DNA damage
while it depends on H2AX phosphorylation.
44 These obser-
vations support that BRIT1 acts early in DNA damage
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response pathways.
BRIT1’s role in modifying chromosome structure 
Chromatin remodeling is one of the fundamental mechani-
sms used by cells to relax chromatin during the process of
DNA repair
51,52 Our very recent study reports a novel func-
tion of BRIT1 as a regulator of ATP-dependent chromatin
remodeling complex SWI/SNF in DNA repair.
43 Upon DNA
damage, BRIT1 increases its interaction with SWI/SNF
through the ATM/ATR-dependent phosphorylation BAF170
subunit of this complex. This increase of binding affinity
provides a means by which SWI/SNF can be specifically
recruited to and maintained at DNA lesions since this in-
teraction relaxes the chromatin structure and increases the
access of the repair proteins, including RAD51, to the DNA
damage sites.
43 This chromatin remodeling function of
BRIT1 may also contribute to the increased accessibility of
many other DNA damage responsors, such as ATM, ATR,
NBS1, MDC1, 53BP1, and RPA. Therefore, BRIT1 can
function as a key molecule that links chromatin remodel-
ing with DNA damage response in the control of DNA
repair. In another attempt to identify BRIT1-associated
proteins, it reveals that BRIT1 can physically bind to the
Condensin II complex, which is involved in chromosome
condensation. The interaction between these two proteins
is required for BRIT1-mediated HR repair.
42 BRIT1 can be
indirectly involved in the DNA repair process via the regula-
tion of the chromatin structure.
BRIT1’s functions in HR and NHEJ DNA repair 
HR and NHEJ are the two major pathways to repair DSBs.
1
RAD51, a homolog of the bacterial RecA, is a central exe-
cutioner in homologous recombination (HR), catalyzing
the invasion of the single stranded DNA in a homologous
duplex and facilitating the homology search during the
establishment of joint molecules. A lack of BRIT1 can alle-
viate localization of RAD51 onto the DNA break sites.
43,45,46
Thus, BRIT1 is critically implicated in the HR process.
Using a HR reporter system, we and others have shown
that HR repair efficiency is reduced in both human cells
with BRIT1 depleted by siRNA and in MEFs isolated
from BRIT1 knockout mice.
42,43,45 In addition, NHEJ repair
is impaired when BRIT1 is depleted. Thus, BRIT1 is re-
quired for both HR and NHEJ DNA repair.
43
In addition to in vitro studies, the role of BRIT1 in HR
DNA repair is clearly demonstrated using a BRIT1 knock-
out mouse model we generated recently.
46 In mice, program-
med DSBs are generated by SPO11 during meiosis for the
initiation of meiotic recombination in spermatocytes. In
response to these DNA damages, HR-DNA repair proteins
such as RAD51 and BRCA2 are recruited to repair those
SPO11-initiated DSBs, which ensures the proper process
of meiotic recombination to produce sperm for reproduc-
tion. Interestingly, male BRIT1
-/- mice are infertile with
smaller testes and very few spermatids. BRIT1 deficiency
does not impair spermatogonia or Sertoli cell proliferation.
However, meiotic recombination in spermatocytes is im-
paired and meiosis is arrested at late zygotene of prophase
I accompanying with apoptosis. In addition, RAD51/
BRCA2 foci formation on the meiotic chromosome is
abolished in BRIT1
-/- mice, although DSB formation is not
altered.
46 Thus, BRIT1 is essential for HR DNA repair via
recruitment of RAD51/BRCA2 to the DNA damaged sites.
Consistent with the role of BRIT1 in regulating the
DNA repair function of BRCA2/RAD51, the meiotic
phenotypes in BRIT1
-/- mice are virtually the same as those
observed in mice with a deficiency of BRCA2
53 and DMC1
(a homologue of RAD51).
54,55 In these mice, spermatocytes
are also arrested before or at the transition of zygotene to




form DSBs without the consequent recruitment of RAD51
to the meiotic chromosome.
53 
A very recent report shows that in human cells, BRIT1
binds to the BRCA2/RAD51 complex and this binding is
required for recruitment or retention of the BRCA2/RAD51
complex at the DNA repair sites.
45 We also demonstrate
that mouse BRIT1 can physically associate with RAD51
or BRCA2, and in the absence of BRIT1, recruitment of
RAD51 and BRCA2 to chromatin is remarkably reduced
while their protein levels are not altered.
46 Thus, BRIT1 also
functions directly in DNA repair by directing the recruit-
ment of BRCA2/RAD51 to the DSBs.
Genomic instability in BRIT1-deficient cells and mice
Due to its multiple functions in DDR, it is expected that
BRIT deficiency would lead to genomic instability. Indeed,
in human cancer cells, when BRIT1 is depleted by siRNA,
these cells exhibit spontaneous chromosomal aberrations.
50
The genomic instability induced by a loss of BRIT1 is also
extensively studied using the BRIT1 knockout mouse.
46
BRIT1
-/- mice are more sensitive to irradiation with a shorter
survival compared to the wild-type control mice. Mouse
embryonic fibroblast (MEFs) isolated from the BRIT1
-/-
mice are also more sensitive to irradiation with severe
chromosome breaks in response to irradiation.
46 In addi-
tion, T cells isolated from BRIT1
-/- mice exert more chro-
mosomal aberrations as compared to the wild-types in the
absence of any irradiation, indicating that BRIT1 plays a
BRIT1 DEFICIENCY, GENOMIC
INSTABILITY, AND CANCER 
DEVELOPMENT role in regulating spontaneous DNA damage.
BRIT1 deficiency in human cancers
In humans, BRIT1 is located at chromosome 8p23.1, where
the loss of heterozigosity (LOH) is common in many types
of cancer including breast and ovarian cancer. Recently,
we have demonstrated that the levels of BRIT1 decreased
in several types of human cancer.
50 Using high-density array
comparative genomic hybridization (CGH), we found sub-
stantial decreases in BRIT1 gene copy number in 35 of 87
cases (40%) of advanced epithelial ovarian cancer. Micro-
array data from a public database also showed that BRIT1
mRNA levels are markedly decreased in 19 of 30 cases
(63%) of ovarian cancer specimens relative to BRIT1
mRNA levels in benign ovarian tissue specimens. Moreo-
ver, 72% of the 54 breast cell lines tested show decreases
in the BRIT1 gene copy number. When comparing BRIT1
expression between non-transformed breast epithelial cells
and established breast cancer cell lines, we also found sig-
nificant decreases of BRIT1 RNA and protein expression
in multiple breast cancer lines. In particular, we identified
a BRIT1 gene deletion in one of the 10 cancer specimens
analyzed which led to the loss of BRIT1 function in DNA
damage response. Thus, BRIT1 is aberrant in human
cancers and it suggests BRIT1 may function as a novel
tumor suppressor gene.
BRIT1 deficiency and cancer development in mice
Genomic instability is observed in our BRIT1 knockout
mice.
46 Although BRIT1 knockout mice within one and half
years old did not develop any tumor, when we crossed
BRIT1 knockout mice to the p53 null background, we found
a significant effect of BRIT1 deficiency in enhancing cancer
susceptibility (unpublished data). Notably, our very recent
preliminary data indicate that low dosage of irradiation can
readily induce breast tumors in the mice with conditional
knockout of BRIT1 in the mammary glands but not in the
control littermates. It will be very interesting to investigate
if, and to what extent, BRIT1 deficiency may contribute to
the initiation and progression of cancer with the existence of
oncogenic or genotoxic stress. For example, we can assess
whether crossing an activated Ras or HER2 allele into the
BRIT1 deficient background will result in increased
genomic instability and tumorigenesis compared to either
mouse strain alone. Thus, our BRIT1 null mouse will be a
very valuable model for further assessing BRIT1’s role in
genome maintenance and tumor suppression in the future.
Perspective for targeting BRIT1 deficient-cancers with
PARP inhibitors
DNA damaging agents, such as irradiation and chemo-
drugs (Doxorubicin, Carboplatin, and Cisplatin), are com-
monly used to treat cancer patients in clinics. However, the
majority of DNA damage reagents are not specific and can
cause toxicity in normal cells as well. Recently, based on
the concept of synthetic lethality, poly (ADP-ribose) poly-
merase (PARP) inhibitors have been identified to kill
BRCA1/2 deficient cells with high specificity, bringing
great promise to the BRCA1/2 cancer patients.
56-59 The
underlying mechanism for this specific killing stems from
a delicate synthetic lethal effect. PARP is an enzyme that
facilitates repair of single-strand DNA breaks (SSBs). In
normal cells, DNA damage generated by PARP inhibitors
is well tolerated because of functional compensation from
the HR-mediated DNA repair pathway.
56,59 In contrast, HR-
repair-defective cancer cells, such as BRCA1- or BRCA2-
deficient cells, are unable to cope with this increased DNA
damage and thereby exhibit hypersensitivity to PARP inhi-
bitors.
56-59 Given that the loss of BRIT1 impairs the BRCA2/
RAD51 DNA repair function and leads to defective HR
repair,
42,43,46 it is possible that PARP inhibitors may serve as
potent drugs specifically targeting BRIT1-deficient cancers.
Recently, we performed an initial study and found that
BRIT1
-/- MEFs were more sensitive to PARP inhibitor
olaparib as compared to BRIT1
+/+ MEFs, suggesting that
PARP inhibitors may be used to effectively treat BRIT1-
deficient cancers. To further test this idea in the future, it is
important to assess the response of the BRIT1-deficient
cancers to potent PARP inhibitors using both cell culture
and xenograft tumor models. It will also be worthwhile to
test the effect of the combination of these PARP inhibitors
with anti-cancer agents currently used in clinics to develop
the optimal therapeutic remedies to target BRIT1-deficient
cancers.
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